Translating the WHA resolution in a member state: towards a German programme on 'Destigmatization' for individuals with visible chronic skin diseases.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
04
10
2018
accepted:
23
04
2019
pubmed:
16
5
2019
medline:
17
4
2020
entrez:
16
5
2019
Statut:
ppublish
Résumé
Even today, a substantial number of individuals with visible skin diseases still suffer from incomprehension and stigmatization. About 10 million people are affected by such diseases in Germany. The WHO strongly urges member states to take measures against stigmatization in skin diseases. Objectives are the development of an action programme to raise awareness and address stigmatization. Therefore, conception, development and testing of interventions for the destigmatization of persons with skin diseases in Germany will be carried out. A series of actions addressing decision makers, politicians and the Federal Ministry of Health were initiated, all based on the World Health Assembly (WHA). Argumentation was largely based on data from health services research. Supported by the Federal Ministry of Health, a concept against stigmatization was developed by an expert consortium of researchers, dermatologists and patients. Specific strategies of structured destigmatization between those affected and those not will be developed and scientifically evaluated. The activities addressed to politics were - to a large extent - successfully and financially supported by a 3-year programme (2018-2020), designed to develop interventions against stigma. It was funded by the Federal Ministry of Health. The project includes conception and development, intervention and evaluation, data analyses and development of a long-term concept. The WHO's call against stigmatization in psoriasis (resolution WHA67.9 and global report on psoriasis 2016) was taken into account and developed into a destigmatization programme supported by the German government and German politicians. This has been achieved by successful collaborations between dermatologists, researchers, patients and policymakers. Next step will be the testing of interventions in situations and surroundings, where stigmatization usually occurs. The data will be used for the implementation of a long-term concept that can be used to continue destigmatization in Germany far beyond the project's initial phase.
Sections du résumé
BACKGROUND
BACKGROUND
Even today, a substantial number of individuals with visible skin diseases still suffer from incomprehension and stigmatization. About 10 million people are affected by such diseases in Germany. The WHO strongly urges member states to take measures against stigmatization in skin diseases.
OBJECTIVES
OBJECTIVE
Objectives are the development of an action programme to raise awareness and address stigmatization. Therefore, conception, development and testing of interventions for the destigmatization of persons with skin diseases in Germany will be carried out.
METHODS
METHODS
A series of actions addressing decision makers, politicians and the Federal Ministry of Health were initiated, all based on the World Health Assembly (WHA). Argumentation was largely based on data from health services research. Supported by the Federal Ministry of Health, a concept against stigmatization was developed by an expert consortium of researchers, dermatologists and patients. Specific strategies of structured destigmatization between those affected and those not will be developed and scientifically evaluated.
RESULTS
RESULTS
The activities addressed to politics were - to a large extent - successfully and financially supported by a 3-year programme (2018-2020), designed to develop interventions against stigma. It was funded by the Federal Ministry of Health. The project includes conception and development, intervention and evaluation, data analyses and development of a long-term concept.
CONCLUSIONS
CONCLUSIONS
The WHO's call against stigmatization in psoriasis (resolution WHA67.9 and global report on psoriasis 2016) was taken into account and developed into a destigmatization programme supported by the German government and German politicians. This has been achieved by successful collaborations between dermatologists, researchers, patients and policymakers. Next step will be the testing of interventions in situations and surroundings, where stigmatization usually occurs. The data will be used for the implementation of a long-term concept that can be used to continue destigmatization in Germany far beyond the project's initial phase.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2202-2208Subventions
Organisme : Federal Ministry of Health
ID : ZMVI1-2517FSB809
Informations de copyright
© 2019 European Academy of Dermatology and Venereology.
Références
Augustin M, Herberger K, Hintzen S, Heigel H, Franzke N, Schäfer I. Prevalence of Skin Lesions and Need for Treatment in a Cohort of 90 880 Workers. Br J Dermatol 2011; 165: 865-873.
Plewig G, Ruzicka T, Kaufmann R, Hertl M. Braun-Falco's Dermatologie, Venerologie und Allergologie, 6th edn. Springer, Heidelberg, Berlin, New York, 2012.
Hart V, Gieler U. Psychosomatische Dermatologie, 1st edn. Springer, Heidelberg, Berlin, New York, 2006.
Fortune DG, Richards HL, Griffiths CE. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin 2005; 23: 681-694.
Augustin M. Cumulative Life Course Impairment: Identifiying Patients at Risk. In: Kimball AB, Linder MD, Itin P, Jemec G, eds. Dermatological Diseases and Cumulative Life Course Impairment. Current Problems in Dermatology, Vol. 44. Karger, Basel, 2013: 74-81.
Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-372.
Warren RB, Kleyn CE, Gulliver WP. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol 2011; 164(Suppl 1): 1-14.
Ros S, Puig L, Carrascosa JM. Cumulative life course impairment: the imprint of psoriasis on the patient's life. Actas Dermosifiliogr 2014; 105: 128-134.
Beikert FC, Langenbruch AK, Radtke MA, Kornek T, Purwins S, Augustin M. Willingness to pay and quality of life in patients with atopic dermatitis. Arch Dermatol Res 2014; 306: 279-286.
Lange S, Zschocke I, Seidenglanz K, et al. Predictors of the quality of life in patients with atopic dermatitis. Dermatol Psychosom 2000; 1: 66-70.
Gutknecht M, Krensel M, Augustin M. Health economic analyses of psoriasis management: a systematic literature search. Arch Dermatol Res 2016; 308: 601-616.
Augustin M, Chapnik J, Gupta S, Buesch K, Radtke M. Psoriasis causes high costs, reduces productivity at work and quality of life. Akt Dermatol 2011; 37: 353-359.
Mrowietz U, Steinz K, Gerdes S. Psoriasis: to treat or to manage? Exp Dermatol 2014; 23: 705-709.
Radtke MA, Reich K, Spehr C, Augustin M. Treatment goals in psoriasis routine care. Arch Dermatol Res 2015; 307: 445-449.
WHO. Global Report on Psoriasis. 2016. Available at: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf (last accessed 09 January 2018).
Richards HL, Fortune DG, Main CJ, Griffiths CEM. Stigmatization and psoriasis. Br J Dermatol 2003; 149: 209-211.
Vardy D, Besser A, Amir M, Gesthalter B, Biton A, Buskila D. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol 2002; 147: 736-742.
Schmid-Ott G, Jaeger B, Kuensebeck HW, Ott R, Lamprecht F. Dimensions of stigmatization in patients with psoriasis in a “questionnaire on experience with skin complaints”. Dermatology 1996; 193: 304-310.
Sommer R, Mrowietz U, Radtke MA, et al. Was ist Schuppenflechte? - Wahrnehmung und Bewertung der Psoriasis in der deutschen Bevölkerung. J Dtsch Dermatol Ges 2018; 16: 703-710.
Sommer R, Mrowietz U, Zander N, Augustin M. “Schuppenflechte” oder “Psoriasis”? Wortwahl und Bekanntheit der Fachbegriffe in der Öffentlichkeit. Hautarzt 2018; 69: 1050-1052.
Young M. The psychological and social burdens of psoriasis. Dermatol Nurs 2005; 17: 15-19.
Łakuta P, Marcinkiewicz K, Bergler-Czop B, Brzezińska-Wcisło L. The relationship between psoriasis and depression: a multiple mediation model. Body Image 2016; 19: 126-132.
Łakuta P, Marcinkiewicz K, Bergler-Czop B, Brzezińska-Wcisło L. How does stigma affect people with psoriasis? Postepy Dermatol Alergol 2017; 34: 36-41.
Alpsoy E, Polat M, FettahlıoGlu-Karaman B, et al. Internalized stigma in psoriasis: a multicenter study. J Dermatol 2017; 44: 885-891.
Kunz HD. Selbsthilfe bei Schuppenflechte. Psoriasis aus Sicht des Deutschen Psoriasis Bundes e. V. (DPB). Gesellschaftspolitische Kommentare 2014; 55(Suppl 1): 18-20.
van Beugen S, van Middendorp H, Ferwerda M, et al. Predictors of perceived stigmatization in patients with psoriasis. Br J Dermatol 2017; 176: 687-694.
Ghorbanibirgani A, Fallahi-Khoshknab M, Zarea K, Abedi H. The lived experience of psoriasis patients from social stigma and rejection: a qualitative study. Iran Red Crescent Med J 2016; 18: e27893.
Hrehorów E, Salomon J, Matusiak L, Reich A, Szepietowski JC. Patients with psoriasis feel stigmatized. Acta Derm Venereol 2012; 92: 67-72.
Daníelsdóttir S, O'Brien KS, Ciao A. Anti-fat prejudice reduction: a review of published studies. Obes Facts 2010; 3: 47-58.
World Health Assembly. Resolution WHA67.9. 2014. Available at: http://apps.who.int/gb/ebwha/pdf_files/wha67/a67_r9-en.pdf (last accessed 15 September 2018).
Augustin M, Eissing L, Langenbruch A, et al. The German national program on psoriasis health care 2005-2015: results and experiences. Arch Dermatol Res 2016; 308: 389-400.